Business Information
The group's principal activities are to develop, manufacture and distribute a broad range of prescription and non-prescription pharmaceuticals under the icn brand name. These pharmaceutical products treat viral and bacterial infections, diseases of the skin, neuromuscular disorders, cancer, cardiovascular disease, diabetes and psychiatric disorders. The group's research and new product development, which exists primarily in its majority owned subsidiary ribapharm inc., focuses on innovative treatments for dermatology, infectious diseases and cancer. The group operates in two segments. The pharmaceuticals group produces and markets a variety of pharmaceutical products worldwide. Ribapharm derives royalty revenues from sales of certain of its products by a third party under a license agreement. In 2003, sold it's russian pharmaceuticals segment and assets of it's biomedicals segment, dosimetry. On Feb 25, 2004, it acquired amarin pharmaceuticals, inc.
|
|
Name |
Title
|
Email
|
| Robert Ingram | Chmn. | N/A | | Charles Bramlage | Pres. - Europe | N/A | | Wesley Wheeler | Pres. - North America Global Product Development | N/A | | Geoffrey Glass | CIO, Sr. VP | N/A | | Janet Hammond | Chief Medical Officer - Research, Development | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 907,238 | (56,565) | | 2005 | 823,886 | (188,142) | | 2004 | 682,520 | (169,797)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
